Andrew Cheng, President and CEO at Akero Therapeutics, Inc. (AKRO), sold 56,117 shares at $43.02 ($2.4M) on 2025-09-11, disclosed to the SEC on 2025-09-12.
Scheduled sale ($2.4M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.99 | 22,525 | $968K | 40.0% |
| 2 | $42.99 | 22,525 | $968K | 40.0% |
| 3 | $44.00 | 7,317 | $322K | 13.3% |
| 4 | $44.62 | 158 | $7K | 0.3% |
| 5 | $43.02 | 1,796 | $77K | 3.2% |
| 6 | $43.02 | 1,796 |
| $77K |
| 3.2% |
| Total | $43.13 avg | 56,117 | $2.4M | 100% |
| Filing → |
| AKRO | SELL | 2025-07-11 | $3.1M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $726K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $4.1M | — | Filing → |